American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 882-884 , June 2008

Reducing Exposure to Calcineurin Inhibitors After Kidney Transplantation

  • Aparna Padiyar, MD

      Affiliations

    • Case Western Reserve University, Cleveland, Ohio
    • University Hospitals Case Medical Center, Cleveland, Ohio
    • ,
  • Donald E. Hricik, MD

      Affiliations

    • Case Western Reserve University, Cleveland, Ohio
    • University Hospitals Case Medical Center, Cleveland, Ohio
    • Corresponding Author InformationAddress correspondence to Donald E. Hricik, MD, Department of Medicine, University Hospitals Case Medical Center, 11000 Euclid Ave, Cleveland, OH 44106.

References 

  1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580–590
  2. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease: major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995;60:452–457
  3. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996;7:158–165
  4. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185
  5. Markell M. Clinical impact of posttransplant diabetes mellitus. Transplant Proc. 2001;33(suppl 5):19S–22S
  6. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78:557–565
  7. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575
  8. Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol. 2003;14:2980–2984
  9. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant. 2007;7:560–570
  10. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001;71:1282–1287
  11. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation. 2007;83:883–892
  12. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006;6:514–522
  13. Flechner S, Glyda M, Steinberg S, et al. A randomized, open-label study to compare the safety and efficacy of two different sirolimus regimens with a tacrolimus and mycophenolate mofetil regimen in de novo renal allograft recipients: acute rejection and graft survival results from the ORION study. Am J Transplant. 2007;7(suppl 2):160

PII: S0272-6386(08)00752-X

doi: 10.1053/j.ajkd.2008.04.006

American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 882-884 , June 2008

Article Tools